<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101300157</journal-id>
<journal-id journal-id-type="pubmed-jr-id">33818</journal-id>
<journal-id journal-id-type="nlm-ta">J Clin Lipidol</journal-id>
<journal-id journal-id-type="iso-abbrev">J Clin Lipidol</journal-id>
<journal-title-group>
<journal-title>Journal of clinical lipidology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1933-2874</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29198934</article-id>
<article-id pub-id-type="pmc">5816714</article-id>
<article-id pub-id-type="doi">10.1016/j.jacl.2017.10.021</article-id>
<article-id pub-id-type="manuscript">NIHMS925441</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Novel Polymorphisms Associated with Hyperalphalipoproteinemia (HALP) and Apparent Cardioprotection</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Oates</surname>
<given-names>Connor</given-names>
</name>
<degrees>BA</degrees>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Koenig</surname>
<given-names>Darya</given-names>
</name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rhyne</surname>
<given-names>Jeffrey</given-names>
</name>
<degrees>BA</degrees>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bogush</surname>
<given-names>Nikolay</given-names>
</name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name>
<surname>O’Connell</surname>
<given-names>Jeffrey</given-names>
</name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mitchell</surname>
<given-names>Braxton D.</given-names>
</name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miller</surname>
<given-names>Michael</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<aff id="A1">Department of Medicine, Divisions of Cardiovascular Medicine and Endocrinology, University of Maryland School of Medicine and the Veterans Affairs Medical Center, Baltimore MD 21201</aff>
</contrib-group>
<author-notes>
<corresp id="FN1"><label>*</label>Author of correspondence: 110 S Paca St, Rm 7-124, Baltimore, MD 21201, <email>mmiller@som.umaryland.edu</email>, Work: 410 328-6299, Fax: 410 328-1048</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>29</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>21</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<season>Jan-Feb</season>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2019</year>
</pub-date>
<volume>12</volume>
<issue>1</issue>
<fpage>110</fpage>
<lpage>115</lpage>
<!--elocation-id from pubmed: 10.1016/j.jacl.2017.10.021-->
<abstract>
<sec id="S1">
<title>Background</title>
<p id="P1">Hyperalphalipoproteinemia (HALP) is inversely correlated with coronary heart disease (CHD) although genetic variants associated with high serum levels of HDL-C have not been shown to be cardioprotective.</p>
</sec>
<sec id="S2">
<title>Objective</title>
<p id="P2">To uncover novel genetic variants associated with HALP and possibly with reduced risk of CHD.</p>
</sec>
<sec id="S3">
<title>Methods</title>
<p id="P3">Exome sequencing data, HDL-C and triglyceride (TG) levels were analyzed in 1645 subjects. They included the University of Maryland outpatients with high HDL-C (n=12), Cardiovascular Health Study (CHS) (n=210), Jackson Heart Study (JHS) (n=402), Multi-Ethnic Study of Atherosclerosis (MESA) (n=404), Framingham Heart Study (FHS) (n=463) and old Order Amish (n=154).</p>
</sec>
<sec id="S4">
<title>Results</title>
<p id="P4">Novel nonsynonymous SNPs (nsSNPs) were identified in men and women with primary HALP (mean HDL-C, 145 +/− 30 mg/dL). Using PolyPhen-2 and Combined Annotation Dependent Depletion (CADD) to estimate the predictive effect of each nsSNP on the gene product, rare, deleterious polymorphisms in <italic>UGT1A3, PLLP, PLEKHH1, ANK2, DIS3L, ACACB</italic> and <italic>LRP4</italic> were identified in 16 subjects with HALP but not in any tested subject with low HDL-C (&lt; 40 mg/dL). In addition, a single novel polymorphism, rs376849274, was found in <italic>OSBPL1A</italic>. The majority of these candidate genes have been implicated in fat and lipid metabolism and none of these subjects has a history of CHD despite 75% of subjects having risk factors for CHD. Overall, the probability of finding these nsSNPs in a non-high HDL-C population ranges from 1 × 10<sup>−17</sup> to 1 × 10<sup>−25</sup>.</p>
</sec>
<sec id="S5">
<title>Conclusion</title>
<p id="P5">Novel functional polymorphisms in 8 candidate genes are associated with HALP in the absence of CHD. Future study is required to examine the extent to which these genes may affect HDL function and serve as potential therapeutic targets for CHD risk reduction.</p>
</sec>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>